Plasma adrenomedullin levels, body fluid status, and end-stage renal failure by Toepfer, Marcel et al.
Letter to the Editor
Nephron 1998;80:232–233
Plasma Adrenomedullin Levels,
Body Fluid Status, and End-Stage
Renal Failure
M. Toepfera
S.M. Langa
G. Hartmannb
T. Sitter a
H. Schiffla
Departments of
a Nephrology and
b Clinical Pharmacology, Medizinische
Klinik, Klinikum Innenstadt, Ludwig
Maximilians University, Munich, Germany
Marcell Toepfer, MD
Medizinische Klinik, Klinikum Innenstadt
Ludwig Maximilians University, Ziemssenstrasse 1
D–80336 Munich (Germany)
Tel. +49 (89) 5160 2220, Fax +49 (89) 5160 4924
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 1998 S. Karger AG, Basel
0028–2766/98/0802–0232$15.00/0
Accessible online at:
http://BioMedNet.com/karger
Dear Sir,
Adrenomedullin (AM), a recently discov-
ered 52-amino-acid peptide hormone, has
biological actions on various organs, most of
which appear to be involved in the regula-
tion of cardiovascular function (vasodila-
tion, positive inotropism) and body fluid/
electrolyte homeostasis (natriuresis and di-
uresis). Recently, it has been speculated that
this peptide may be important both as a
paracrine and an autocrine factor and may
serve as a classical circulating hormone [1].
The origins of AM in the plasma of
healthy subjects, typically in the low picomo-
lar range, are uncertain. However, circulat-
ing AM concentrations are increased in
chronic renal failure, and they are strongely
correlated with the severity of the disease [2].
To date the mechanisms contributing to the
2- to 4-fold increase in AM levels in patients
with end-stage renal disease remain unde-
fined. Clearance or metabolism and in-
creased synthesis or secretion have not been
elucidated in dialysis patients with coexist-
ing disorders of body fluid volume status.
Forty-four patients with end-stage renal
disease receiving regular hemodialysis (3–
4 h three times per week, volumetrically con-
trolled ultrafiltration, low-flux membranes)
were selected from a large outpatient popula-
tion. End-stage renal disease was caused by
different etiologies, high blood pressure was
defined by repeated predialysis recordings
(RR 1 140/80 mm Hg), and heart failure was
classified by clinical symptoms and verified
by X-rays of the chest and echocardiogra-
phy.
Fig. 1. Plasma concentrations of AM in three subgroups of patients on hemodialysis and
in controls: group I were normotensive patients without heart failure; group II hypertensive
patients without heart failure, and group III consisted of normotensive patients with heart
failure NYHA classes II–IV.
These patients were assigned to three
groups: group I (n = 25) were patients with
end-stage renal disease only; group II (n =
15) patients with end-stage renal disease
complicated by hypervolemic hypertension,
and group III (n = 14) consisted of patients
with end-stage renal disease and congestive
heart failure according to the New York
Heart Association (NYHA) classes III and
IV.
Healthy subjects (n = 24) with normal
renal function, blood pressure, and heart
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function served as controls. The three groups
of patients did not differ in age, gender,
duration of hemodialysis, and residual renal
function. The plasma concentrations of AM
were measured with a specific radioimmu-
noassay for human AM (1–52), as previously
described elsewhere [3]. The coefficients of
variation were !5% for the intra-assay and
8% for the interassay determinations.
The plasma AM concentrations were sig-
nificantly increased in each patient with
end-stage renal disease as compared with
matched control subjects (67.9 B 15.4 vs.
27.1 B 4.6 pg/ml; p ! 0.001). The circulating
AM concentrations were significantly higher
in hypervolemic hypertensive patients as
compared with normotensive dialysis pa-
tients (71.4 B 15.4 vs. 58.0 B 13.2 pg/ml; p
! 0.01; fig. 1). Furthermore, the plasma AM
levels in patients with end-stage renal failure
and heart failure of NYHA classes III or IV
were significantly higher as compared with
those of patients without signs of heart dis-
ease (74.3 B 14.9 vs. 58.0 B 13.2 pg/ml; p !
0.01).
The major results of our investigation
confirm reports of other authors [4, 5] who
found an increase in plasma AM levels in
patients with end-stage renal disease on he-
modialysis. But our data demonstrate for the
first time that circulating AM concentrations
are affected by the coexistence of cardiovas-
cular disorders. Since other investigators re-
ported that plasma AM levels are positively
correlated with serum creatinine concentra-
tions, one might accept that the elevation of
AM in chronic renal failure is associated
with a decreased clearance of the peptide in
failing kidneys [6]. However, the progressive
rise in circulating AM levels in hypervolemic
cardiovascular disorders [7], the close corre-
lation between plasma levels of AM and the
volume marker atrial natriuretic peptide [8,
9], as well as the fall in plasma AM by iso-
lated ultrafiltration, but not by isovolemic
hemodialysis [10], all indicate that plasma
AM in end-stage renal disease is elevated by
increased synthesis/secretion. There is com-
pelling evidence that AM is secreted by the
failing human heart in proportion to the
increase in left ventricular filling pressure. In
conclusion, we are aware that changes in cir-
culating AM occur in end-stage renal dis-
ease, but it is premature to identify a cause-
and-effect relationship between increased
AM concentrations and pathological states
of the cardiovascular system.
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